Abstract: The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.

Abstract: The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.

Abstract: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin ?V?3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin ?V?3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin ?V?3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin ?V?3 antagonists which can be used according to the methods of the invention.

Abstract: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin &agr;V&bgr;3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin &agr;V&bgr;3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin &agr;V&bgr;3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer.

Abstract: A system for forming and collating printed signatures is disclosed in which a plurality of web supply rolls feed a plurality of continuously operating presses. A rewinding mechanism is provided to form printed web rolls which may be stored until printing has been completed for the entire publication. Slitting apparatus is provided longitudinally to cut each printed web into a plurality of printed ribbons which are thereafter collated to form one or more composite signature ribbons. Folding apparatus continuously folds each signature ribbon longitudinally and the folded ribbons are cross associated to form a compound ribbon moving substantially parallel to the gathering conveyor. The compound ribbon is cut into individual signature sets which are conveyed to the gathering conveyor.BACKGROUND OF THE INVENTIONThe present invention relates to a method for printing and collating individual signatures to be assembled into a magazine or book, or the like.